CClinicalTrials.gg
CompletedNCT05824884Updated May 7, 2026

Self-efficacy Enhancement in a Virtual Reality Training for Fear of Heights

An interventional study of Visual Feedback and Self-efficacy enhancement: in Fear of Heights and Specific Phobia, Situational, sponsored by Ruhr University of Bochum. Completed at 1 site in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-07.

Sponsored by Ruhr University of Bochum · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
83
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Self-efficacy (SE) enhancement after virtual reality exposure (VRET) for heights can promote treatment-induced effects (Raeder et al. 2019). Raeder et al (2019) employed an intervention to enhance SE by introducing specific questions about autobiographical events of success and mastery experiences in the course of VRET. Building on these previous findings, the present study aims to examine whether SE-enhancement DURING and/or AFTER a brief VR-based exposure for fear of heights (in the following referred to as VR-height-exposure) is suitable to promote exposure-induced reductions in height-related fear and avoidance. To this end, repeated visual feedback DURING a brief VR-height-exposure will be used to selectively promote SE and mastery experiences. In a similar vein, SE-enhancement AFTER VR-height-exposure will be administered. The effects of these interventions will be assessed on different treatment outcome levels. It will be further examined whether the combined SE enhancement (DURING and AFTER exposure) is more effective that 1.) SE enhancement performed DURING VR-height-exposure only or 2.) SE enhancement performed AFTER VR-height-exposure only.

The investigators hypothesize that SE enhancement (either administered DURING or AFTER VR-height-exposure) will be more effective (as indicated by more pronounced reductions in height-related fear and avoidance) than VR-height-exposure alone. It is further expected that the combined SE enhancement DURING and AFTER VR-height-exposure will be more effective compared to SE enhancement DURING VR-height-exposure alone and/or SE enhancement DURING VR-height-exposure alone.

Read the detailed description

The aim of this study is to evaluate whether visual feedback DURING VR-height-exposure and SE-enhancement strategies that are designed to promote mastery experience AFTER exposure are suitable to benefit exposure-induced reductions in height-related fear and avoidance.

Participants will be randomly assigned to one of the following conditions: a) visual feedback DURING VR-height-exposure and SE-enhancement targeting mastery experience AFTER VR-height-exposure b) no visual feedback DURING VR-height-exposure but SE-enhancement targeting mastery experience AFTER VR-height-exposure, c) visual feedback DURING VR-height-exposure but a control intervention AFTER VR-height-exposure d) no visual feedback and control intervention after VR-height- exposure. The SE-enhancement as well as the control intervention involve memory reactivation either with or without emphasis on a mastery experience attained during the VR-height-exposure. The visual feedback is presented in form of a progress-update combined with positive affirmation.

The VR-height-exposure concludes different exercises in a virtual environment that simulate situations, that can be challenging to height-fearful individuals in real life, such as glass-elevators, a glass-bridge, a tall ladder and lattice stairs. During VR-height-exposure, self-reported fear is measured in Subjective Units of Distress (SUDS). The VR-environment is presented via head-mounted displays and the participants can use touch-controllers to navigate through the exercises guided by the experimenter.

As outcome measures, subjective fear and height-related avoidance will be assessed at three time points: pre-exposure, post-exposure and at 3 months-follow-up.

Subjective fear is measured using the Acrophobia Questionnaire (AQ; Cohen, 1977). To measure height-related avoidance behavior, a Behavioural Approach Test (BAT) will be performed in a nearby church tower, that includes 13 steps of varying difficulty and requires active behavioral approach towards height-situations.

Furthermore, danger expectancies and fear expectancies (DES, AES) will be measured at pre- and post-exposure as well as at 3-months-follow-up. During all BATs and the VR-height-exposure, heart-rate variability (HRV) will be assessed as a psychophysiological indicator for fear response.

Moreover, participants are asked to rate their general self-efficacy via Questionnaire (GSE) and their perceived self-efficacy via Visual Analogue Scales (VAS) at pre- and post-exposure as well as 3-months follow-up. Furthermore, the VAS measures mood, excitement, and distraction.

Additionally, several control variables are assessed pre-exposure, including Beck's Depression Inventory II (BDI-II), The State-and-Trait-Anxiety Inventory (STAI-T; STAI-S), the Self-Efficacy Scale (SES) and the CSSES.

Implicit Approach-Avoidance biases towards height-related stimuli will also be assessed pre- and post VR-height-training utilizing the Approach-Avoidance-Task (AAT). The participants are instructed to push away (simulating avoidance) vs. pull towards (simulating approach) neutral vs. height-related pictures according to the way they are tilted (tilted-right vs. tilted left) using the computer mouse. Reaction time delays in the pull towards height-related pictures condition can be an indicator for implicit avoidance tendencies.

02

Conditions studied

  • Fear of Heights
  • Specific Phobia, Situational

Keywords

  • Specific phobia
  • fear of heights
  • Self-efficacy
  • virtual reality
  • exposure
03

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • age 18 to 65 years
  • fear of heights
  • normal or corrected vision

Exclusion criteria

Exclusion Criteria:

  • acute psychotherapy or psychotherapy in the past 2 years
  • acute psychiatric drug intake
  • acute schizophrenic or psychotic symptoms
  • acute major depressive episode with severe symptoms
  • acute substance use disorder
  • neurological disorder or mental disability
  • cardiac arrhythmias or pacemaker
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
83 participants (actual)

Study arms

  • Experimental
    Experimental 1

    positive visual feedback during VR-height-exposure combined with SE-enhancement after exposure.

    Behavioral: Visual Feedback · Behavioral: Self-efficacy enhancement:

  • Active comparator
    Active Comparator 1

    positive visual feedback during VR-height-exposure, and a placebo intervention after exposure.

    Behavioral: Visual Feedback · Behavioral: placebo intervention

  • Active comparator
    Active Comparator 2

    no visual feedback during exposure but SE-enhancement after exposure.

    Behavioral: Self-efficacy enhancement: · Behavioral: No visual feedback

  • Placebo comparator
    Placebo Comparator

    no visual feedback during exposure and placebo intervention after exposure.

    Behavioral: placebo intervention · Behavioral: No visual feedback

Interventions

  • BehavioralVisual Feedback

    Visual progress feedback and words of positive affirmation will be presented triggered by checkpoints set in the VR-height-exposure.

  • BehavioralSelf-efficacy enhancement:

    specific instructions regarding the retrieval of mastery experiences during exposure will be given (modified version of the procedure used in Raeder et al. 2019).

  • Behavioralplacebo intervention

    specific instructions regarding the retrieval of the exposure session will be given without an emphasis on personal mastery experience (modified version of the procedure used in Raeder et al. 2019).

  • BehavioralNo visual feedback

    Participants can not trigger any checkpoints during VR and therefore not receive any progress feedback or positive affirmation.

05

What researchers measure

Primary outcomes

  1. Change in the Behavioural Approach Test (BAT)

    Time frame: from baseline to 24 hours after exposure and 3-months-follow-up

  2. Change in Acrophobia Questionnaire (AQ)

    Time frame: from baseline to 24 hours after exposure and 3-months-follow-up

  3. Change in subjective fear during the BAT

    Subjective fear during the BATs will be measured using the Subjective Units of Distress Scale (SUDS)

    Time frame: from baseline to 24 hours after exposure and 3-months-follow-up

  4. Changes in Heart Rate Variability (HRV) during the BAT

    Time frame: at baseline, 24 hours after exposure and at 3-months-follow-up

Secondary outcomes

  1. Change in Danger Expectancy Scale (DES)

    Time frame: from baseline to 24 hours after exposure and 3-months-follow-up

  2. Change in Anxiety Expectancy Scale (AES)

    Time frame: from baseline to 24 hours after exposure and 3-months-follow-up

  3. Differences in GSE between the respective groups

    ANOVA with mean GSE-scores

    Time frame: at pre-exposure, immediately after exposure and 3-months-follow-up

  4. Differences in AQ between the respective groups

    ANOVA with mean AQ-scores

    Time frame: at baseline, 24 hours after exposure and 3-months-follow-up

Other outcomes

  1. Change in perceived SE from pre to post VR-height-exposure

    Changes in perceived SE will be measures with visual analogue scales (VAS)

    Time frame: from baseline to 24 hours after exposure and 3-months-follow-up

  2. Becks Depression Inventory II (BDI)

    Time frame: assessed at baseline

  3. State-Trait Anxiety Inventory (STAI-T/STAI-S)

    Time frame: assessed at baseline

  4. Self-Efficacy Scale (SES)

    Time frame: assessed at baseline

  5. Chronic Stress Self-Efficacy Scale (CSSES)

    Time frame: assessed at baseline

  6. Avoidance Bias in height-fearful individuals

    An Avoidance Bias will be assessed utilizing the AAT

    Time frame: assessed at baseline

  7. Changes in Avoidance Bias

    Time frame: from baseline to 24 hours after exposure

06

Study locations

1 site
  • Mental Health Research and Treatment Center
    Bochum, 44787, Germany
07

Registry details

Key details

Study ID
NCT05824884
Lead sponsor
Ruhr University of Bochum
Responsible party
Armin Zlomuzica (Principal Investigator, Ruhr University of Bochum) — Principal investigator
First posted
Apr 24, 2023
Start date
Jun 22, 2023
Primary completion
Mar 30, 2026
Completion
Mar 30, 2026
Last update
May 7, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion